Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05726110
NCT05726110RecruitingPhase 3

A Single-arm Open-label Multicenter Clinical Study of Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Shanxi Bethune Hospital1 site in 1 country50 target enrollmentStarted: January 29, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
50
Locations
1
Primary Endpoint
Remission Rate
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia

Detailed Description

Main Purpose：

To observe the efficacy of selinexor in combination with HAD or CAG regimen for relapsed and refractory acute myeloid leukemia :complete remission rate (CR rate), partial remission rate (PR rate), no remission rate (NR rate), complete remission with incomplete hematologic recovery(CRi rate)

Secondary Purposes：

  1. To observe the recurrence rate of selinexor combined with HAD or CAG regimen for relapsed and refractory acute myeloid leukemia, treatment-related mortality(TRM), Overall Survival (OS), Event-Free Survival (EFS);
  2. Safety indicators: to observe adverse events and deaths during treatment with selinexor in combination with HAD or CAG regimen.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age:18-60 years old;
  • •Except for patients with AML-M3 with acute myeloid leukemia；
  • •Meet the diagnostic criteria for refractory AML (2011 Chinese guidelines for the diagnosis and treatment of acute myeloid leukemia (relapsed or refractory)):(1) The standard regimen did not achieve complete remission after 2 courses of induction chemotherapy;(2) Relapse within 6 months after the first complete remission; (3) Patients who relapse after 6 months after the first complete remission, and those who fail to induce chemotherapy after the original program; (4) 2 or more recurrences; (5) Extramedullary leukemia persists；
  • •Meet the diagnostic criteria for recurrent AML (refer to the 2014 NCCN guidelines): after complete remission, (1) naive cells appear in peripheral blood; (2) >5% of bone marrow naive cells; (3) Extramedullary recurrence；
  • •The bone marrow image indicates active hyperplasia or hypoproliferation；
  • •Eastern Oncology Collaborative Group Physical Status Assessment (ECOG-PS) with a score of 0-2.

Exclusion Criteria

  • •Accompanied by cerebral hemorrhage；
  • •Have a mental illness or other condition that cannot proceed as planned；
  • •Severe arrhythmia, abnormal ECG (QT>500ms).
  • •Early withdrawal from test criteria：
  • •Participants have the right to withdraw from the study at any time from the trial. Exit Criteria:
  • •The subject or the subject's legally authorized representative requests to withdraw from the study;
  • •Participant loss to follow-up.
  • •Doctor/Investigator required subjects to terminate the trial early:
  • •Subjects who are unable to carry out follow-up treatment due to adverse events (serious irreversible organ function damage during treatment) who are judged by the investigator to be unsuitable for continuing the research;
  • •The subject does not adhere to the protocol, such as the use of chemotherapy drugs, etc., which affects the effectiveness and safety judgment.
  • •For participants who withdrew early from the study (except subjects who were lost to follow-up), the reason for their early withdrawal should be recorded, and the time of the last study's medication/treatment should be recorded, and the examination items at the time of early withdrawal from the study should be completed at the last visit, if possible.

Arms & Interventions

Selinexor、HAD or CAG regimens

Experimental
  • Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML.
  • (Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg/ m^2/d)×7days, daunorubicin (DNR, 40mg/ m^2/d)×3 days, cytarabine (Ara-C,100-200mg/ m^2/d)×7 days (no leukocyte drugs should be used throughout the treatment process)；
  • (Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug/kg/d, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg/d)×4 days (d1-4), cytarabine (10 mg/ m^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14).
  • G-CSF was discontinued in the CAG regimen when WBC > 20×10^9/L, but chemotherapy was not stopped.

Intervention: Selinexor (Drug)

Selinexor、HAD or CAG regimens

Experimental
  • Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML.
  • (Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg/ m^2/d)×7days, daunorubicin (DNR, 40mg/ m^2/d)×3 days, cytarabine (Ara-C,100-200mg/ m^2/d)×7 days (no leukocyte drugs should be used throughout the treatment process)；
  • (Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug/kg/d, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg/d)×4 days (d1-4), cytarabine (10 mg/ m^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14).
  • G-CSF was discontinued in the CAG regimen when WBC > 20×10^9/L, but chemotherapy was not stopped.

Intervention: Homoharringtonine (Drug)

Selinexor、HAD or CAG regimens

Experimental
  • Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML.
  • (Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg/ m^2/d)×7days, daunorubicin (DNR, 40mg/ m^2/d)×3 days, cytarabine (Ara-C,100-200mg/ m^2/d)×7 days (no leukocyte drugs should be used throughout the treatment process)；
  • (Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug/kg/d, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg/d)×4 days (d1-4), cytarabine (10 mg/ m^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14).
  • G-CSF was discontinued in the CAG regimen when WBC > 20×10^9/L, but chemotherapy was not stopped.

Intervention: Daunorubicin (Drug)

Selinexor、HAD or CAG regimens

Experimental
  • Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML.
  • (Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg/ m^2/d)×7days, daunorubicin (DNR, 40mg/ m^2/d)×3 days, cytarabine (Ara-C,100-200mg/ m^2/d)×7 days (no leukocyte drugs should be used throughout the treatment process)；
  • (Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug/kg/d, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg/d)×4 days (d1-4), cytarabine (10 mg/ m^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14).
  • G-CSF was discontinued in the CAG regimen when WBC > 20×10^9/L, but chemotherapy was not stopped.

Intervention: Cytarabine (Drug)

Selinexor、HAD or CAG regimens

Experimental
  • Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML.
  • (Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg/ m^2/d)×7days, daunorubicin (DNR, 40mg/ m^2/d)×3 days, cytarabine (Ara-C,100-200mg/ m^2/d)×7 days (no leukocyte drugs should be used throughout the treatment process)；
  • (Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug/kg/d, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg/d)×4 days (d1-4), cytarabine (10 mg/ m^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14).
  • G-CSF was discontinued in the CAG regimen when WBC > 20×10^9/L, but chemotherapy was not stopped.

Intervention: Granulocyte Colony-Stimulating Factor (Drug)

Selinexor、HAD or CAG regimens

Experimental
  • Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML.
  • (Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg/ m^2/d)×7days, daunorubicin (DNR, 40mg/ m^2/d)×3 days, cytarabine (Ara-C,100-200mg/ m^2/d)×7 days (no leukocyte drugs should be used throughout the treatment process)；
  • (Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug/kg/d, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg/d)×4 days (d1-4), cytarabine (10 mg/ m^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14).
  • G-CSF was discontinued in the CAG regimen when WBC > 20×10^9/L, but chemotherapy was not stopped.

Intervention: Aclacinomycin (Drug)

Outcomes

Primary Outcomes

Remission Rate

Time Frame: max 2 years

complete remission rate(CR rate), partial remission rate (PR rate) , no remission rate (NR rate)

Secondary Outcomes

  • Recurrence Rate(max 2 years)
  • Treatment-Related Mortality (TRM)(max 2 years)
  • Overall Survival (OS)(max 2 years)
  • Event-Free Survival (EFS)(max 2 years)
  • Safety:Incidence and severity of adverse events(max 2 years)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) PatientsRelapsed/Refractory AML
NCT05805072The First Affiliated Hospital of Soochow University20
Not yet recruiting
Phase 2
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCTMDSAML, Adult
NCT06765928Ruijin Hospital73
Active, not recruiting
Phase 1
Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)Maximum Tolerated DoseMetastatic Adult Soft Tissue SarcomaDrug ToxicityDrug UseGIST
NCT04138381Grupo Espanol de Investigacion en Sarcomas30
Terminated
Phase 1
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense ChemotherapyAcute Myeloid Leukemia, Adult
NCT06449482Institute of Hematology & Blood Diseases Hospital, China6
Recruiting
Phase 2
Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell LymphomaDLBCL Germinal Center B-Cell Type
NCT05422066Li Zhiming50